Details of the PSS

General Information of Protein Scaffold of SBP (PSS) (ID: PS018)
PSS Name	BiTE
Synonyms	Bispecific T cell engager
Diagrammatic Sketch
Highest Status	Marketed
Class	Antibody fragment
Fold Type	Beta-Sheets + Loops
Sequence Length	495-990
Molecular Weight	55-100 kDa

Parental Protein of This PSS

Parental Protein Name	Synonym		PDB ID	UniProt ID	Origin
Antibody	N.A.		N.A.	N.A.	Human; Mouse; Synthetic construct

Synthetic Binding Protein (SBP) Featuring this PSS

SBP Name	Highest Status	Template	Expression System	Selection Method	Details	Ref
BiTE Blinatumomab	Marketed	N.A.	Escherichia coli	N.A.	SBP Info	[1], [2], [3]
BiTE Solitomab	Phase II	N.A.	Chinese hamster ovary cells	N.A.	SBP Info	[2], [4]
BiTE Acapatamab	Phase I	N.A.	N.A.	N.A.	SBP Info	[5]
BiTE AMG-199	Phase I	N.A.	N.A.	N.A.	SBP Info	[5], [6]
BiTE AMG-211	Phase I; Discontinued	N.A.	N.A.	N.A.	SBP Info	[7], [8]
BiTE AMG-427	Phase I	N.A.	N.A.	N.A.	SBP Info	[9], [5]
BiTE AMG-562	Phase I	N.A.	N.A.	N.A.	SBP Info	[5], [6]
BiTE AMG-673	Phase I; Suspended	N.A.	N.A.	N.A.	SBP Info	[5]
BiTE AMG-910	Phase I	N.A.	N.A.	N.A.	SBP Info	[5]
BiTE Eluvixtamab	Phase I	N.A.	N.A.	N.A.	SBP Info	[10], [5]
BiTE Etevritamab	Phase I; Discontinued	N.A.	N.A.	N.A.	SBP Info	[5], [6], [7]
BiTE Pacanalotamab	Phase I	N.A.	N.A.	N.A.	SBP Info	[6], [11]
BiTE Pasotuxizumab	Phase I	N.A.	N.A.	N.A.	SBP Info	[2], [12]
BiTE Pavurutamab	Phase I; Suspended	N.A.	N.A.	N.A.	SBP Info	[5]
BiTE Tarlatamab	Phase I	N.A.	N.A.	N.A.	SBP Info	[5]
BiTE anti-PSMA 5D3-alphaCD3	Research	N.A.	Schneiders S2 cells	N.A.	SBP Info	[13]
BiTE anti-CD19/CD3 AMG103	Research	N.A.	N.A.	N.A.	SBP Info	[14]
BiTE anti-CD3/SV2B	Research	N.A.	N.A.	N.A.	SBP Info	[15]
BiTE anti-CD38/CD3E	Research	N.A.	N.A.	N.A.	SBP Info	[16]
BiTE anti-EpCAM/CD3 MuS110	Research	N.A.	N.A.	N.A.	SBP Info	[2], [17]
BiTE anti-FAPalpha	Research	N.A.	N.A.	N.A.	SBP Info	[18]
BiTE anti-TfR/CD3	Research	N.A.	N.A.	N.A.	SBP Info	[19]

References

1	Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011 May 15;317(9):1255-60.
2	Recent advances in the development of novel protein scaffolds based therapeutics. Int J Biol Macromol. 2017 Sep;102:630-641.
3	DRUGBANK online. Blinatumomab
4	MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006 Mar;43(8):1129-43.
5	Amgen. Product Development Pipeline. 2021.
6	The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020 Jul 15;126(14):3192-3201.
7	Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow. Mol Ther Oncolytics. 2019 Mar 23;14:38-56.
8	Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89 Zr-AMG211 Targeting CEA-Positive Tumors. Clin Cancer Res. 2018 Oct 15;24(20):4988-4996.
9	Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia. Mol Cancer Ther. 2020 Sep;19(9):1875-1888.
10	Harnessing T cells to fight cancer with BiTE? antibody constructs--past developments and future directions. Immunol Rev. 2016 Mar;270(1):193-208.
11	B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020 Apr;34(4):985-1005.
12	Amgen. Product Development Pipeline. 2019.
13	Targeting Prostate Cancer Using Bispecific T-Cell Engagers against Prostate-Specific Membrane Antigen. ACS Pharmacol Transl Sci. 2023 Oct 6;6(11):1703-1714.
14	Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Front Immunol. 2020 May 7;11:762.
15	High throughput development of TCR-mimic antibody that targets survivin-2B 80-88/HLA-A*A24 and its application in a bispecific T-cell engager. Sci Rep. 2019 Jul 8;9(1):9827.
16	Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma. Haematologica. 2021 Apr 1;106(4):1193-1197.
17	Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res. 2008 Jan 1;68(1):143-51.
18	Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. J Immunother Cancer. 2019 Jan 25;7(1):19.
19	Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor. Front Immunol. 2019 Jun 21;10:1396.